85916-97-8

Basic information

• Product Name: 5,8,11,14,17-eicosapentaenoyl chloride
• Synonyms: 5,8,11,14,17-eicosapentaenoyl chloride
• CAS NO: 85916-97-8
• Molecular Weight: 320.903
• Mol File: 85916-97-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5,8,11,14,17-eicosapentaenoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 5,8,11,14,17-eicosapentaenoyl chloride(85916-97-8)
• EPA Substance Registry System: 5,8,11,14,17-eicosapentaenoyl chloride(85916-97-8)

Safety Data

• Hazardous Substances Data: 85916-97-8(Hazardous Substances Data)

Upstream product

• 1553-41-9 5,8,11,14,17-eicosapentaenoic acid 

Downstream Products

• 140670-39-9 glyceryl-1-(5,8,11,14,17-eicosapentaenoate) 

Relevant articles and documents

Compositions and methods for the suppression of carbonic anhydrase activity

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing or modulating carbonic anhydrase activity in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of glaucoma, epileptic seizures, Idiopathic intracranial hypertension (pseudotumor cerebri), altitude sickness, cystinuria, periodic paralysis and dural ectasia, congestive heart failure, drug induced edema, diuretic, intermittent claudication resulting from obstructed arteries in the limbs, and vascular dementia.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucus diseases related to painful inflammation and ulceration of the digestive tract lining and in the mouth.

COMPOSITIONS AND METHODS FOR SUPPRESSION OF CARBONIC ANHYDRASE ACTIVITY

Provided are the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for treating or preventing or modulating carbonic anhydrase activity in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral admimstration, syrup, or injection. Such compositions may be used to treatment of glaucoma, epileptic seizures, Idiopathic intracranial hypertension (pseudotumor cerebri), altitude sickness, cystinuria, periodic paralysis and dural ectasia, congestive heart failure, drug induced edema, diuretic, intermittent claudication resulting from obstructed arteries in the limbs, and vascular dementia.